BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 27656711)

  • 1. Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
    Weitz JI; Haas S; Ageno W; Angchaisuksiri P; Bounameaux H; Nielsen JD; Goldhaber SZ; Goto S; Kayani G; Mantovani L; Prandoni P; Schellong S; Turpie AG; Kakkar AK
    Thromb Haemost; 2016 Nov; 116(6):1172-1179. PubMed ID: 27656711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing U.S. and Canadian treatment patterns on venous thromboembolism outcomes in the GARFIELD-VTE registry.
    Chen AC; Rao AS; Oropallo A; Goldhaber SZ; Fluharty ME; Maheshwari U; Carrier M; Turpie AGG; Pieper K; Kayani G; Kakkar AK;
    Thromb Res; 2023 Dec; 232():123-132. PubMed ID: 37976732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
    Cohen AT; Gitt AK; Bauersachs R; Fronk EM; Laeis P; Mismetti P; Monreal M; Willich SN; Bramlage P; Agnelli G; Prefer In Vte Scientific Steering Committee And The Prefer In Vte Investigators OBOT
    Thromb Haemost; 2017 Jun; 117(7):1326-1337. PubMed ID: 28405675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.
    Ageno W; Haas S; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Nielsen JD; Kayani G; Pieper KS; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
    Thromb Haemost; 2019 Feb; 119(2):319-327. PubMed ID: 30593086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
    Haas S; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Zaghdoun A; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
    J Thromb Haemost; 2019 Oct; 17(10):1694-1706. PubMed ID: 31220403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE.
    Weitz JI; Haas S; Ageno W; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Nielsen JD; Kayani G; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
    J Thromb Thrombolysis; 2020 Aug; 50(2):267-277. PubMed ID: 32583306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry.
    Barillari G; Londero AP; Brenner B; Nauffal D; Muñoz-Torrero JF; Del Molino F; Moustafa F; Madridano O; Martín-Martos F; Monreal M;
    Eur J Intern Med; 2016 Jul; 32():53-9. PubMed ID: 26972931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
    Akwaa F; Spyropoulos AC
    Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
    Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.
    Goto S; Haas S; Ageno W; Goldhaber SZ; Turpie AGG; Weitz JI; Angchaisuksiri P; Nielsen JD; Kayani G; Farjat A; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
    JAMA Netw Open; 2020 Oct; 3(10):e2022886. PubMed ID: 33112399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism in centenarians: Findings from the RIETE registry.
    Lacruz B; Tiberio G; Núñez MJ; López-Jiménez L; Riera-Mestre A; Tiraferri E; Verhamme P; Mazzolai L; González J; Monreal M;
    Eur J Intern Med; 2016 Dec; 36():62-66. PubMed ID: 27495947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Ageno W; Casella IB; Han CK; Raskob GE; Schellong S; Schulman S; Singer DE; Kimura K; Tang W; Desch M; Goldhaber SZ
    Thromb Haemost; 2017 Jan; 117(2):415-421. PubMed ID: 27853808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort.
    Tagalakis V; Patenaude V; Kahn SR; Suissa S
    Thromb Res; 2014 Oct; 134(4):795-802. PubMed ID: 25135794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE.
    Goto S; Turpie AGG; Farjat AE; Weitz JI; Haas S; Ageno W; Goldhaber SZ; Angchaisuksiri P; Kayani G; MacCallum P; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK;
    Thromb Res; 2021 Jul; 203():155-162. PubMed ID: 34023735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous Thromboembolism Recurrence in Latvian Population: Single University Hospital Data.
    Ģībietis V; Kigitoviča D; Strautmane S; Meilande K; Kalējs VR; Zaičenko A; Maķe K; Lejnieks A; Skride A
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31438542
    [No Abstract]   [Full Text] [Related]  

  • 18. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.
    Turpie AGG; Farjat AE; Haas S; Ageno W; Weitz JI; Goldhaber SZ; Goto S; Angchaisuksiri P; Kayani G; Lopes RD; Chiang CE; Gibbs H; Tse E; Verhamme P; Ten Cate H; Muntaner J; Schellong S; Bounameaux H; Prandoni P; Maheshwari U; Kakkar AK;
    Thromb Res; 2023 Feb; 222():31-39. PubMed ID: 36565677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
    Voukalis C; Lip GY; Shantsila E
    Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.